SG11201407775WA - Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta - Google Patents
Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-betaInfo
- Publication number
- SG11201407775WA SG11201407775WA SG11201407775WA SG11201407775WA SG11201407775WA SG 11201407775W A SG11201407775W A SG 11201407775WA SG 11201407775W A SG11201407775W A SG 11201407775WA SG 11201407775W A SG11201407775W A SG 11201407775WA SG 11201407775W A SG11201407775W A SG 11201407775WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- metabolic syndrome
- street
- methods
- hsp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 November 2013 (28.11.2013) WIPOIPCT (10) International Publication Number WO 2013/177535 A2 (51) International Patent Classification: A61K 48/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/US2013/042692 24 May 2013 (24.05.2013) English English (30) Priority Data: 61/652,023 25 May 2012 (25.05.2012) (84) US (71) Applicant: BERG PHARMA LLC [US/US]; 1845 Elm Hill Pike, Nashville, TN 37210 (US). (72) Inventors: NARAIN, Niven, Rajin; 73 Fresh Pond Park way, Cambridge, MA 02138 (US). SARANGARAJAN, Rangaprasad; 45 Central Street, Boylston, MA 01505 (US). VISHNUDAS, Vivek, K.; 91 Stamford Street, Apt. 1, Newton, MA 02466 (US). JING, Enxuan; 200 Maple Street, West Roxbury, MA 02132 (US). (74) Agents: HANLEY, Elizabeth, A. et al.; Mccarter & Eng lish, LLP, 265 Franklin Street, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — without international search report and to be republished upon receipt of that report (Rule 48.2(g)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: METHODS OF TREATING A METABOLIC SYNDROME BY MODULATING HEAT SHOCK PROTEIN (HSP) 90- BETA Delta-Delta Networks DD_NG.vs.HG.vs.HGT 1 ,cys [ NG vs. HG ] vs. [ HS vs. HGT1 ] CJ m i> i> T-H rn T-H O (57) Abstract: The invention provides methods of treatment of metabolic syndrome with HSP90 inhibitors, particularly HSP90P in- ^ hibitors. The invention provides methods of diagnosis and monitoring of metabolic syndrome using HSP90, particularly HSP90p, Q expression and activity level.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261652023P | 2012-05-25 | 2012-05-25 | |
PCT/US2013/042692 WO2013177535A2 (en) | 2012-05-25 | 2013-05-24 | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201407775WA true SG11201407775WA (en) | 2014-12-30 |
Family
ID=49624539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201407775WA SG11201407775WA (en) | 2012-05-25 | 2013-05-24 | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
Country Status (15)
Country | Link |
---|---|
US (2) | US9533002B2 (en) |
EP (1) | EP2854865B1 (en) |
JP (1) | JP6478908B2 (en) |
KR (1) | KR20150010793A (en) |
CN (1) | CN104812898B (en) |
AU (1) | AU2013266086B2 (en) |
BR (1) | BR112014029301A2 (en) |
CA (1) | CA2874676A1 (en) |
EA (1) | EA201492184A1 (en) |
HK (1) | HK1209035A1 (en) |
IL (1) | IL235910A0 (en) |
MX (1) | MX2014014188A (en) |
NZ (1) | NZ702169A (en) |
SG (1) | SG11201407775WA (en) |
WO (1) | WO2013177535A2 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201492184A1 (en) * | 2012-05-25 | 2015-07-30 | Берг Ллк | METHODS OF TREATMENT OF METABOLIC SYNDROME BY MODULATING PROTEIN HEAT SHOCK (HSP) 90-BETA |
RU2650646C2 (en) | 2012-09-27 | 2018-04-16 | Дзе Чилдрен'З Медикал Сентер Корпорейшн | Compounds for the treatment of obesity and methods of use thereof |
CA3044998A1 (en) * | 2014-03-26 | 2015-10-01 | The Children's Medical Center Corporation | Celastrol and derivatives for the treatment of obesity |
US10023864B2 (en) | 2014-06-06 | 2018-07-17 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
EP3154547B1 (en) * | 2014-06-13 | 2023-06-07 | Yuma Therapeutics, Inc. | Pyrimidine compounds and methods using the same |
US20180110978A1 (en) * | 2015-03-19 | 2018-04-26 | Old Dominion University Research Foundation | Synergistic regulated cell death induction with hsp90 inhibitors and nanosecond pulsed electric fields |
US10662218B2 (en) * | 2015-10-23 | 2020-05-26 | Erx Pharmaceuticals, Inc. | Analogs of celastrol |
CN105920018B (en) * | 2016-06-15 | 2019-01-11 | 上海市内分泌代谢病研究所 | Celastrol combines the purposes of jamaicin preparation treatment antiobesity agents |
CN107543929A (en) * | 2016-06-23 | 2018-01-05 | 中国医学科学院肿瘤医院 | Kit based on protein marker HSP90AB1 diagnosing patients |
CN107028953A (en) * | 2017-03-27 | 2017-08-11 | 北京大学 | A kind of stimulant of sympathetic activity |
IL296355A (en) * | 2017-04-24 | 2022-11-01 | Samus Therapeutics Inc | Hsp90 inhibitor oral formulations and related methods |
WO2018235251A1 (en) | 2017-06-23 | 2018-12-27 | 株式会社ニコン | Analysis device, analysis program, and analysis method |
CN112156188A (en) * | 2020-11-10 | 2021-01-01 | 上海交通大学医学院附属瑞金医院 | Application of Hsp90 in preparation of drugs for preventing and treating steroid diabetes |
CN113332308A (en) * | 2021-02-22 | 2021-09-03 | 广东省妇幼保健院 | Application of preparation for regulating HSP90B1 expression level in preparation of medicine for preventing or treating polycystic ovarian syndrome |
CN113160983A (en) * | 2021-04-09 | 2021-07-23 | 南京医科大学附属逸夫医院 | Metabolism-related fatty liver disease clinical prediction model |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7078375B1 (en) * | 1996-10-25 | 2006-07-18 | Peter Mose Larsen | Diabetes-mediating proteins and therapeutic uses thereof |
US20040048256A1 (en) * | 2001-09-07 | 2004-03-11 | Agee Michele L. | Novel proteins and nucleic acids encoding same |
WO2004033657A2 (en) | 2002-10-07 | 2004-04-22 | Antigenics, Inc. | Heat shock protein binding fragments of cd91, and uses thereof |
US7189723B2 (en) | 2003-02-10 | 2007-03-13 | Cgi Pharmaceuticals, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
BRPI0413861A (en) | 2003-08-29 | 2006-10-24 | Vernalis Cambridge Ltd | pyrimidothiophene compounds |
US20070249540A1 (en) | 2004-05-24 | 2007-10-25 | Adonia Papathanassiu | Methods for Inhibiting Proteasome and Heat Shock Protein 90 |
CA2574727A1 (en) | 2004-07-19 | 2006-02-23 | University Of Rochester | Biomarkers of neurodegenerative disease |
US20060094682A1 (en) * | 2004-10-29 | 2006-05-04 | Odyssey Thera, Inc. | Kinase inhibitors for the treatment of diabetes and obesity |
US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
FR2885904B1 (en) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | NOVEL FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING SAME AND USE THEREOF |
JP2009504673A (en) | 2005-08-11 | 2009-02-05 | ノバルティス アクチエンゲゼルシャフト | A combination comprising a protein kinase inhibitor which is a pyrimidylaminobenzamide compound and an HSP90 inhibitor such as 17-AAG |
US20070207950A1 (en) | 2005-12-21 | 2007-09-06 | Duke University | Methods and compositions for regulating HDAC6 activity |
WO2007077042A1 (en) | 2006-01-06 | 2007-07-12 | Topotarget Switzerland Sa | New method for the treatment of gout or pseudogout |
WO2007097839A2 (en) | 2006-02-16 | 2007-08-30 | Massachusetts Eye And Ear Infirmary | Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye |
EP2007800A1 (en) | 2006-03-17 | 2008-12-31 | Crossbeta Biosciences B.V. | Methods of binding of cross-beta structures by chaperones |
WO2007137239A2 (en) | 2006-05-19 | 2007-11-29 | The Scripps Research Institute | Treatment of protein misfolding |
JP5441690B2 (en) | 2006-05-25 | 2014-03-12 | シンタ ファーマシューティカルズ コーポレーション | Triazole compounds that modulate Hsp90 activity |
EP2069325A2 (en) | 2006-08-24 | 2009-06-17 | Serenex, Inc. | Isoquinoline, quinazoline and phthalazine derivatives |
WO2008024974A1 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Pyrimidine and pyrazine derivatives |
US20110160175A1 (en) | 2006-09-11 | 2011-06-30 | Christine Martin | 18,21-Didesoxymacbecin Derivatives for the Treatment of Cancer |
JP5721949B2 (en) | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | Compound drug |
JP5518478B2 (en) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | Pharmaceutical compounds |
GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB0622084D0 (en) | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
US7855192B2 (en) | 2007-01-26 | 2010-12-21 | Kosan Biosciences, Inc. | Macrolactams by engineered biosynthesis |
SI2069324T1 (en) | 2007-03-20 | 2013-10-30 | Curis, Inc. | Fused amino pyridine as hsp90 inhibitors |
GB2449293A (en) | 2007-05-17 | 2008-11-19 | Evotec | Compounds having Hsp90 inhibitory activity |
US20100298280A1 (en) | 2007-06-13 | 2010-11-25 | Petra Kioschis-Schneider | Compounds for the Modulation of Huntingtin Aggregation, Methods and Means for Identifying Such Compounds |
IL184671A0 (en) | 2007-07-17 | 2008-12-29 | Hadasit Med Res Service | Substances directed to heparanase c-terminal domain-or substance derived therefrom and uses thereof as modulators of heparanas biological activities |
DE102007041116A1 (en) | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | 1,3-dihydro-isoindole derivatives |
TW200920357A (en) | 2007-09-10 | 2009-05-16 | Curis Inc | HSP90 inhibitors containing a zinc binding moiety |
EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
US20110218143A1 (en) | 2007-11-20 | 2011-09-08 | University Of Florida Research Foundation | Compositions and methods for tissue repair |
EP2226632B1 (en) | 2007-12-28 | 2014-02-12 | Takeda Pharmaceutical Company Limited | Method for screening of cell-protecting agent |
US8461194B2 (en) * | 2008-03-07 | 2013-06-11 | Aziende Chimiche Riunite Angelini Francesco A. C. R. A. F. S. P. A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40 |
WO2009114470A2 (en) | 2008-03-10 | 2009-09-17 | Curis, Inc. | Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety |
EP2100879A1 (en) | 2008-03-13 | 2009-09-16 | 4Sc Ag | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds |
BRPI0822354B1 (en) | 2008-05-19 | 2020-11-10 | Hewlett Packard Development Company, L.P | method to support pre-boot login on computer systems, computer-readable media and computer system |
CN104530052A (en) * | 2008-06-10 | 2015-04-22 | 普莱希科公司 | 5H-Pyrrolo [2,3-B] pyrazine derivatives for kinase modulation, and indications therefor |
WO2010014617A1 (en) | 2008-07-28 | 2010-02-04 | University Of Kansas | Heat shock protein 90 inhibitor dosing methods |
US8299275B2 (en) | 2008-08-04 | 2012-10-30 | Dsm Ip Assets B.V. | Process for producing carnosol from carnosic acid using hydrogen peroxide or peracids |
WO2010019965A1 (en) | 2008-08-15 | 2010-02-18 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection |
US20110230551A1 (en) | 2008-09-15 | 2011-09-22 | Leslie Gunatilaka | Withaferin a analogs and uses thereof |
CN102227221A (en) | 2008-11-28 | 2011-10-26 | 诺瓦提斯公司 | Pharmaceutical combination containing hsp90 inhibitor and mtor inhibitor |
WO2010117425A1 (en) | 2009-03-31 | 2010-10-14 | Biogen Idec Ma Inc. | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
US20130030007A1 (en) * | 2010-01-07 | 2013-01-31 | Akron Molecules Gmbh | Obesity Small Molecules |
US20110201587A1 (en) * | 2010-02-16 | 2011-08-18 | Bio Holding, Inc. | Hsp90 inhibitors and methods of use |
EP2536714A4 (en) | 2010-02-17 | 2013-07-03 | Il Dong Pharma | A novel 5-membered heterocycle derivatives and manufacturing process thereof |
CA2697887A1 (en) | 2010-03-12 | 2011-09-12 | Institut De Recherches Cliniques De Montreal | Modulating and/or detecting activation induced deaminase and methods of use thereof |
WO2011133659A2 (en) | 2010-04-20 | 2011-10-27 | Emory University | Inhibitors of hif and angiogenesis |
US9249087B2 (en) | 2011-02-01 | 2016-02-02 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
US8598339B2 (en) | 2011-02-01 | 2013-12-03 | University Of Kansas | Withanolide isolated from Physalis longifolia and analogs and methods of use thereof |
US8685966B2 (en) | 2011-04-08 | 2014-04-01 | University Of Kansas | GRP94 inhibitors |
WO2013015661A2 (en) | 2011-07-28 | 2013-01-31 | Ildong Pharm Co.,Ltd. | Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide |
EA201492184A1 (en) * | 2012-05-25 | 2015-07-30 | Берг Ллк | METHODS OF TREATMENT OF METABOLIC SYNDROME BY MODULATING PROTEIN HEAT SHOCK (HSP) 90-BETA |
CN102772399A (en) * | 2012-08-16 | 2012-11-14 | 厦门大学 | Application of gambogic acid serving as protein kinase agonist activated by 5'-ampicillin (AMP) |
-
2013
- 2013-05-24 EA EA201492184A patent/EA201492184A1/en unknown
- 2013-05-24 JP JP2015514227A patent/JP6478908B2/en not_active Expired - Fee Related
- 2013-05-24 BR BR112014029301A patent/BR112014029301A2/en not_active IP Right Cessation
- 2013-05-24 WO PCT/US2013/042692 patent/WO2013177535A2/en active Application Filing
- 2013-05-24 CA CA2874676A patent/CA2874676A1/en not_active Abandoned
- 2013-05-24 EP EP13793158.0A patent/EP2854865B1/en active Active
- 2013-05-24 SG SG11201407775WA patent/SG11201407775WA/en unknown
- 2013-05-24 KR KR1020147035410A patent/KR20150010793A/en not_active Application Discontinuation
- 2013-05-24 NZ NZ702169A patent/NZ702169A/en not_active IP Right Cessation
- 2013-05-24 CN CN201380039309.5A patent/CN104812898B/en not_active Expired - Fee Related
- 2013-05-24 AU AU2013266086A patent/AU2013266086B2/en not_active Ceased
- 2013-05-24 MX MX2014014188A patent/MX2014014188A/en unknown
- 2013-05-24 US US13/902,354 patent/US9533002B2/en active Active
-
2014
- 2014-11-25 IL IL235910A patent/IL235910A0/en unknown
-
2015
- 2015-10-05 HK HK15109711.2A patent/HK1209035A1/en unknown
-
2016
- 2016-11-21 US US15/357,915 patent/US20170166891A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2854865B1 (en) | 2019-02-20 |
CA2874676A1 (en) | 2013-11-28 |
EP2854865A4 (en) | 2016-03-02 |
US20170166891A1 (en) | 2017-06-15 |
WO2013177535A8 (en) | 2014-11-13 |
WO2013177535A3 (en) | 2015-03-05 |
CN104812898A (en) | 2015-07-29 |
KR20150010793A (en) | 2015-01-28 |
AU2013266086B2 (en) | 2018-03-01 |
US9533002B2 (en) | 2017-01-03 |
EP2854865A2 (en) | 2015-04-08 |
US20140154266A1 (en) | 2014-06-05 |
CN104812898B (en) | 2018-01-30 |
NZ702169A (en) | 2016-10-28 |
BR112014029301A2 (en) | 2017-07-25 |
AU2013266086A1 (en) | 2014-12-11 |
JP2015520170A (en) | 2015-07-16 |
MX2014014188A (en) | 2015-05-11 |
JP6478908B2 (en) | 2019-03-06 |
EA201492184A1 (en) | 2015-07-30 |
HK1209035A1 (en) | 2016-03-24 |
WO2013177535A2 (en) | 2013-11-28 |
IL235910A0 (en) | 2015-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201407775WA (en) | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta | |
SG11201804647TA (en) | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde | |
SG11201407569PA (en) | Interrogatory cell-based assays for identifying drug-induced toxicity markers | |
SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201407268SA (en) | Nuclear transport modulators and uses thereof | |
SG11201408651TA (en) | Use of markers in the diagnosis and treatment of prostate cancer | |
SG11201408261UA (en) | Syringe | |
SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
SG11201809714TA (en) | Piperidines as menin inhibitors | |
SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
SG11201806861SA (en) | Combination therapy with anti-cd73 antibodies | |
SG11201407370QA (en) | Humanized il-7 rodents | |
SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
SG11201408679XA (en) | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof | |
SG11201909963YA (en) | Methods for treating dravet syndrome | |
SG11201407561UA (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201407890VA (en) | Tetrahydropyrazolopyrimidine compounds | |
SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201407340YA (en) | Treatment of myelosuppression | |
SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
SG11201407981RA (en) | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |